Comprehensive molecular profiling
to
guide personalized cancer treatment

 

The Sema4 Signal portfolio offers multiple somatic profiling solutions to meet service providers’ clinical, research, and trial needs. Our somatic tests generate actionable insights that help providers treat patients today while preparing to take advantage of the insights of tomorrow.

 

Sema4 Signal Whole Exome/Transcriptome Sequencing (WES/WTS)

 

Captures data from ~18,500 genes to provide the most comprehensive molecular picture of a patient’s cancer.

 

Read more.

Sema4 Signal PanCancer

 

Reports findings on ~2,200 of the most relevant cancer driver genes, based on comprehensive WES/WTS data.

 

Read more.

Sema4 Signal Solid Tumor (+MSI)

 

Targets 161 of the most clinically relevant and actionable cancer genes using as little as 10-20 ng of tumor DNA.

 

Read more.

 

Which test best meets my patient’s needs?

 

 Sema4 Signal WES/WTSSema4 Signal PanCancerSema4 Signal
Solid Tumor Panel (+MSI)
Cancer type– Solid tumors
– Hematologic malignancies
– Solid tumors
– Hematologic malignancies
– Solid tumors
Number of genes reported on~18,500~2,200*161
Most suitable for– Providers seeking the broadest data available to inform care

– Researchers

– Clinical Trialists
– Providers looking for the most comprehensive somatic panel– STAT turnaround time

– Smaller sample sizes**
Molecular alterations detected– SNVs/InDels
– Certain splice variants
– CNVs
– Fusions
– SNVs/InDels
– Certain splice variants
– CNVs
– Fusions
– SNVs/InDels
– Certain splice variants
– CNVs
– Fusions
Immuno-oncology biomarkers analyzed– PD-L1
– MMR
– MSI
– TMB
– PD-L1
– MMR
– MSI
– TMB
– PD-L1
– MMR
– MSI
Germline findings reported– Hereditary cancer genes

– Non-cancer genes, as per ACMG guidelines***
– Hereditary cancer genesNo
Post-test genetic counselingFor positive germline findingsFor positive germline findingsNo
Turnaround time14-21 days14-21 days10-14 days

<10 days for STAT

* ~2,200 genes reported on from WES/WTS data (~18,500 genes)

** Offered as reflex testing if WES/WTS or PanCancer not possible

*** ACMG Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing (ACMG SF v2.0). PMID: 27854360

 

WES/WTS and PanCancer Interactive Lookup Tool

Find information on specific cancer genes included in our WES/WTS and PanCancer tests

 

 

State-of-the-art profiling, enabled by cutting-edge informatics

 

Sema4 Signal somatic tests are powered by a number of proprietary data tools, including:

Sema4 cancer knowledgebase

Contains comprehensive, structured data and the most current state of knowledge for over 7,000 variants, including clinical trials curated based on biomarker status by PhD oncology experts.

Sema4’s variant interpretation station for oncology

Automates clinical reporting by managing the variant curation process and recommending suitable therapies. This artificial intelligence-driven genomic platform is updated regularly with the latest literature and prioritizes clinically-significant variants, enabling providers to quickly review and leverage actionable insights.

 


 

Resources

 

Provider Brochure

 

Connect with us today

Feel free to call us at 833-486-6260 or fill out the form below and we’ll schedule a time to discuss your needs.